Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Vaccine. 2014 Apr 13;32(26):3133–3138. doi: 10.1016/j.vaccine.2014.04.019

Table 2.

Characteristics of seven studies from nine study sites included in measurement of VPDI shown in Fig. 1.

Trial (reference) Vaccine Vaccine schedule Follow-up period Episodes Outcome
Rotavirus Africa (Malawi, South Africa) (6) Rotarix (human, live, attenuated, monovalent G1P8 vaccine) 2 or 3 doses at age 6, 10, 14 weeks 2 weeks after last dose to age 1 year All episodes Severe rotavirus gastroenteritis defined by Vesikari score
Rotavirus Asia (Bangladesh, Vietnam) (8) Rotateq (human-bovine reassortment pentavalent) 3 doses at 6, 10,14 weeks 14 days after dose 3 up to 24 months All episodes Severe rotavirus gastroenteritis defined by Vesikari score
Pneumococcus The Gambia (5) 9-valent pneumococcal conjugate vaccine (1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F) 3 doses separated by at least 25 days, age 6–51 weeks at initiation 2 weeks after first dose to illness, withdrawal, death, age 30 months, or study completion First episode Severe all cause pneumonia + confirmed pneumococcal meningitis
Haemophilus influenzae type b (Hib) Indonesia (4) Hib conjugate vaccine (PRP-T) 3 doses a scheduled age of 6,10,14 weeks delivered through routine immunization program 2 weeks after first dose until death, age 2 years, or study completion All episodes Severe all cause pneumonia + either meningitis hospitalization or outpatient seizure
Malaria multi-center older children (15) RTS,S, adjuvanted anti-circumsporozoite vaccine 3 doses at 1 month intervals, age 5–17 months at initiation Age first vaccination to 12 months after dose 3 All episodes Any parasitemia + one or more markers of severe malaria
Malaria multi-center young infants (16) RTS,S, adjuvanted anti-circumsporozoite vaccine 3 doses at 1 month intervals age 6 to 12 weeks at initiation Age first vaccination to 12 months after dose 3 All episodes Any parasitemia + one or more markers of severe malaria
Cholera India (17) Shanchol: oral, killed, whole-cell vaccine with O1 El Tor Inaba, O1 classical Ogawa, O1 classical Inaba, and O139 V. cholerae 2 doses at 1 month intervals, age 1–4 years at initiation 14 to 730 days after first vaccination First episodes Confirmed cholera (3+ stools in 24 h, or <3 stools with dehydration, plus V. cholerae identification in stool)